Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration

  title={Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration},
  author={Barbara M Davit and P E Nwakama and Gary Buehler and Dale P. Conner and Samer Haidar and Devvrat T. Patel and Yongsheng Yang and Lawrence X. Yu and Janet Woodcock},
  journal={Annals of Pharmacotherapy},
  pages={1583 - 1597}
Background: In the US, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the generic formulation provides the same rate and extent of absorption as (ie, is bioequivalent to) the innovator drug product. Thus, most orally administered generic drug products in the US are approved based on results of one or more clinical bioequivalence studies. Objective: To evaluate how well the bioequivalence measures of generic drugs approved in the US over a 12… 

Figures and Tables from this paper

International Guidelines for Bioequivalence of Systemically Available Orally Administered Generic Drug Products: A Survey of Similarities and Differences

There are more similarities than differences in bioequivalence approaches among the regulatory authorities surveyed and the Biopharmaceutics Classification System is observed.

Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness

Product-specific approaches to demonstrating therapeutic equivalence are essential to avoid delays in low-cost generic drug availability but can have important clinical implications; yet, currently, there is no formal process in place to monitor the safety and effectiveness of generic drugs approved using modified regulatory pathways.


The belief that generic drugs are inferior to brand name drugs has been always under debate. Especially since the price of generic drugs is generally far cheaper than brand-name drugs. Although, this

Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug Administration

A reference-scaled average bioequivalence (RSABE) approach, whereby the BE acceptance limits are scaled to the variability of the reference product, has been implemented successfully and supported four full approvals and one tentative approval of HV generic drug products.

Drug Information Association Pharmacovigilance and Risk Management Strategies 2017: Overview of the Generic Drug Program and Surveillance

The FDA Office of Generic Drugs’ (OGD’s) Clinical Safety Surveillance Staff (CSSS) has developed investigative processes that complement the broader FDA safety efforts that focus on the potential impact of allowable differences and equivalence determinations for generic drugs.

An Integrated Bioinformatics and Quantitative Modeling Approach to Investigate Potential Claims of Oral Generic Drug Product Bioinequivalence: Introduction

It is imperative that complaints about generic drug substitution be investigated thoroughly to determine if the generic drug is actually meeting bioequivalence standards and if there is a rational, mechanistic explanation for the purported reduction in benefits or increase in risks attributed to theGeneric drug.

Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs

On-market generic drug products continue to be reference-bioequivalent and are bioequivalent to each other based on AUCT, AUCI, and Cmax but not AUCReftmax, and average deviation of geometric mean ratios and intra-subject variations are similar between reference-generic and generic-generic comparisons.

Pharmacokinetics and Generic Drug Switching: A Regulator’s View

It is described why it is of the opinion that the current regulatory approach to the evaluation of generic drugs based on average bioequivalence is sufficient to expect therapeutic equivalence in the clinical setting.

The Safety of Generic Prescription Drugs in the United States

Concerns about safety of generics are not limited to patients, but extend to other stakeholders including physicians and pharmacists, and the lack of quality control at several product manufacturing sites of prominent manufacturers outside the USA has accentuated concerns about their safety.

Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial

This study prospectively assesses bioequivalence between innovator tacrolimus and 2 generics in individuals with a kidney or liver transplant and finds no statistically significant differences among any pairs of products were found for any adverse event code or for adverse events overall.



Highly Variable Drugs: Observations from Bioequivalence Data Submitted to the FDA for New Generic Drug Applications

It was observed that most of the consistent and borderline highly variable drugs underwent extensive first pass metabolism and drug product dissolution variability was high for about half of the inconsistentlyhighly variable drugs.

Generic substitution: issues for problematic drugs.

Information and myths persist regarding the adequacy and proven reliability of the FDA's determination of bioequivalence for digoxin and levothyroxine tablets.

What’s the problem with generic antiepileptic drugs?

Two pharmacokinetic measures, the area under the drug concentration-time curve (AUC) and maximum concentration (Cmax), are used to determine bioequivalence (and by extension from these surrogate measures, therapeutic equivalence), and two reviews have been conducted by the FDA.

Generic drugs and the prescribing physician.

FDA procedures for approving generic drug products are described and the role of the states in generic substitution and the availability of information from the FDA on the therapeutic equivalence of drug products is described.

Drug substitution in transplantation: a National Kidney Foundation White Paper.

Generic antiepileptic drugs

  • S. ShawG. Krauss
  • Medicine, Political Science
    Current treatment options in neurology
  • 2008
Although generic AEDs are generally safe and effective for most patients, the current bioequivalence standards may not be sufficient for certain patient populations and for certain drugs, requiring vulnerable patients to be monitored very carefully when converting to generic Aeds.

Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

Clinical evidence does not support the notion that brand-name drugs used in cardiovascular disease are superior to generic drugs, and a substantial number of editorials counsel against the interchangeability of generic drugs.

Understanding the scientific issues embedded in the generic drug approval process.

Evaluation of Bioequivalence of Highly Variable Drugs Using Clinical Trial Simulations. II: Comparison of Single and Multiple-Dose Trials Using AUC and Cmax

It was showed that multiple-dose designs for highly variable drugs do not always reduce intrasubject variability in either AUC or Cmax, although the behavior of AUC differs from Cmax.

Comparison of Single and Multiple Dose Pharmacokinetics Using Clinical Bioequivalence Data and Monte Carlo Simulations

The probability of failing the bioequivalence test is shown to dramatically decrease upon multiple dosing due to the changes (range and shift) in the confidence interval.